Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex

Rapamycin inhibits the mTOR (target of rapamycin) pathway and extends lifespan in multiple species. The tuberous sclerosis complex (TSC) protein is a negative regulator of mTOR. In humans, loss of the TSC protein results in a disorder characterized clinically by the growth of benign tumors in multip...

Descripción completa

Detalles Bibliográficos
Autor principal: Major, Philippe
Formato: Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Commentaries & Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091516/
https://www.ncbi.nlm.nih.gov/pubmed/21415462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091516/
https://www.ncbi.nlm.nih.gov/pubmed/21415462

Ejemplares similares